Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen.
Publication/Presentation Date
12-1-2007
Abstract
Colorectal cancer is a leading cause of cancer-related mortality worldwide. Surgery and chemoradiation exhibit incomplete efficacy and, ultimately, 50% of patients die of metastatic disease. In the context of that unmet clinical need, immunotherapeutic approaches have enjoyed limited success, partly because of a paucity of suitable antigen targets. However, exploitation of immune compartmentalization, employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors--cancer mucosa antigens (CMAs)--may represent a previously unrecognized class of immune targets supporting efficacious antitumor immunotherapy. Guanylyl cyclase C (GCC) is an intestine/colorectal cancer-restricted protein ideally suited as the first CMA for clinical evaluation.
Volume
82
Issue
6
First Page
734
Last Page
739
ISSN
1532-6535
Published In/Presented At
Snook, A. E., Eisenlohr, L. C., Rothstein, J. L., & Waldman, S. A. (2007). Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clinical pharmacology and therapeutics, 82(6), 734–739. https://doi.org/10.1038/sj.clpt.6100369
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
17898707
Department(s)
Administration and Leadership
Document Type
Article